title: [Pazopanib for three patients with recurrence of retroperitoneal liposarcoma : initial clinical experience].
abstract: Pazopanib, a novel tyrosine kinase inhibitor, is an effective therapeutic agent for patients with advanced soft tissue sarcoma. Here we report three patients with recurrent retroperitoneal liposarcoma who were treated with pazopanib. Case 1: A 54-year-old male received three courses of combined chemotherapy consisting of doxorubicin and ifosfamide for recurrent left retroperitoneal dedifferentiated liposarcoma and liver metastasis following tumor excision. Because of the lack of response to chemotherapy, 400 mg/day of pazopanib was subsequently administered for two weeks. The patient died 3 weeks after the initiation of pazopznib therapy. Case 2: A 78-year-old male with right retroperitoneal dedifferentiated liposarcoma underwent irradiation for a recurrent tumor 16 months after the initial tumor excision. Pazopanib (600 mg/day) was partially effective for 2 months. Pazopanib was administered for 7 months, but the patient died 8 months after the initiation of pazopanib therapy. Case 3 : An 80-year-old male with locally recurrent right retroperitoneal myxoid liposacroma was treated with 600 mg/day of pazopanib from 5 months after tumor excision. He remains alive and has had stable disease for 17 months to date. In conclusion, pazopanib may be effective in a subset of patients with recurrent retroperitoneal liposarcoma.
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Koizumi
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Takamitsu
authors.initials: T
authors.lastname: Inoue
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Takayama
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Makoto
authors.initials: M
authors.lastname: Takahashi
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Numakura
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tsuruta
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Susumu
authors.initials: S
authors.lastname: Akihama
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Saito
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Shintaro
authors.initials: S
authors.lastname: Narita
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Norihiko
authors.initials: N
authors.lastname: Tsuchiya
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Shigeru
authors.initials: S
authors.lastname: Satoh
authors.affiliation: The Department of Urology, Akita University School of Medicine.
authors.forename: Tomonori
authors.initials: T
authors.lastname: Habuchi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007191:Indazoles; D008080:Liposarcoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D013449:Sulfonamides / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib